RxDoctor Payments Data

Maureen Horton

Pulmonary Disease · San Francisco, CANPI 1861446189

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $16,925 of the $16,925 with a category attached, or 100.0%. Boehringer Ingelheim International GmbH accounts for 72.1% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2021 at $7,800 and has fallen 74.4% since, to $2,000 in 2022.

$16,925in general payments, 2019–2025

Across 8 payments — averaging $2115.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$12K
  • Janssen Research & Development, LLC$5K
$600,554in research payments, 2019–2025

Across 7 payments — averaging $85,793 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$516K
  • Biogen$55K
  • Novartis$30K

What the payments were for

  • Consulting fees$16,925100%

General payments by program year

20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,925 in reported general payments places this provider in the 85th percentile of 1,261 pulmonary disease providers in California.

See all pulmonary disease providers in California

Other pulmonary disease in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →